---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-001357"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:30:26.929548+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma CEO buys voting-preferred shares for $10K; 1-for-200 reverse split approved

## Summary
- CEO Steve Slilaty purchased 100,000 Series B Preferred shares for $10,000, each with 1,000 votes.
- Preferred stock is non-convertible, non-redeemable, with $0.10 liquidation preference superior to common.
- Slilaty, holder of ~57.4% voting power, approved by written consent a reverse stock split up to 1-for-200.
- Reverse split up to 1-for-200 aims to regain Nasdaq $1.00 minimum bid; effective 20 days after mailing info statement filed March 5.

## SEC filing metadata
- accession: 0001683168-24-001357
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001357/0001683168-24-001357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001357/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-001357
- JSON: https://secwatch.observer/filing/0001683168-24-001357.json
- Plain text: https://secwatch.observer/filing/0001683168-24-001357.txt

## Key facts
- Shareholder Votes
  Sunshine Biopharma Inc. shareholders approved Reverse stock split of the Company’s common stock at a ratio up to 1-for-200 at the 2024-03-04 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2024-03-04
  source text: On March 4, 2024, Dr. Slilaty, as the holder of the majority of the voting power of the stockholders of the Company, approved by written consent to effect a reverse stock split of the Company’s common stock at a ratio up to 1-for-200.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001357/0001683168-24-001357-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.